Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Jun 04, 2023 11:02am
210 Views
Post# 35479112

RE:RE:It's on Twitter... ASCO Results

RE:RE:It's on Twitter... ASCO ResultsThe SP is going to drop by at least 25% if ONC fails to deliver updated results on Monday morning. 

And based on the cursory glance at the ASCO slides, it appears ONC will have nothing new to say. 

Damn, I hope I'm wrong.

Keep in mind that as recently as the March Investor Presentation on their website, ONC was telling us OS data would be presented H! 2023 (ie. ASCO).

And now they may have nothing fresh since the ASCO cutoff of October 2022??

Did I say 25%? No, more likely a 30 or 35% drop.

How can a company over promise and under deliver for 22 years and remain a going concern (rhetorical question, answer at this time is of course ATM).

I think Monday morning is ONC's last chance before yet another reverse split. 

Given his leading comments and tone coming into ASCO, Matt Coffey should be fired if ONC fails to delilver something newsworthy. 
<< Previous
Bullboard Posts
Next >>